The U.S. Food and Drug Administration (FDA) has recently granted approval for Johnson & Johnson's Inlexzo (gemcitabine intravesical system), a new treatment option for certain bladder cancer patients. This includes adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, who have had unsuccessful BCG therapy or are ineligible for radical cystectomy. Inlexzo (previously known as TAR-200) is designed for patients who wish to preserve their bladder. This approval provides these patients with additional options in their treatment journey.